标题
FBP1
induced by β‐elemene enhances the sensitivity of gefitinib in lung cancer
作者
关键词
-
出版物
Thoracic Cancer
Volume 14, Issue 4, Pages 371-380
出版商
Wiley
发表日期
2022-12-17
DOI
10.1111/1759-7714.14750
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- β-Elemene Restrains PTEN mRNA Degradation to Restrain the Growth of Lung Cancer Cells via METTL3-Mediated N6 Methyladenosine Modification
- (2022) Yuxu Feng et al. Journal of Oncology
- Age-period-cohort analysis of lung cancer mortality in China and Australia from 1990 to 2019
- (2022) Ning Wang et al. Scientific Reports
- Targeting nicotinamide N-methyltransferase overcomes resistance to EGFR-TKI in non-small cell lung cancer cells
- (2022) Jun Wang et al. Cell Death Discovery
- Fructose‐1,6‐bisphosphatase aggravates oxidative stress‐induced apoptosis in asthma by suppressing the Nrf2 pathway
- (2021) Jiapeng Hu et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Recent Update on Development of Small-Molecule STAT3 Inhibitors for Cancer Therapy: From Phosphorylation Inhibition to Protein Degradation
- (2021) Jinyun Dong et al. JOURNAL OF MEDICINAL CHEMISTRY
- FBP1 regulates proliferation, metastasis, and chemoresistance by participating in C-MYC/STAT3 signaling axis in ovarian cancer
- (2021) Haoran Li et al. ONCOGENE
- Targeting STAT3 signaling overcomes gefitinib resistance in non-small cell lung cancer
- (2021) Zhe Liu et al. Cell Death & Disease
- High expression of FBP1 and LDHB in fibroadenomas and invasive breast cancers
- (2021) Ika Yustisia et al. Breast Disease
- FBP1 enhances the radiosensitivity by suppressing glycolysis via the FBXW7/mTOR axis in nasopharyngeal carcinoma cells
- (2021) Pengfei Zhang et al. LIFE SCIENCES
- Targeting MERTK and AXL in EGFR Mutant Non-Small Cell Lung Cancer
- (2021) Dan Yan et al. Cancers
- FBP1 loss disrupts liver metabolism and promotes tumorigenesis through a hepatic stellate cell senescence secretome
- (2020) Fuming Li et al. NATURE CELL BIOLOGY
- Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial
- (2020) Yi-Long Wu et al. Lancet Respiratory Medicine
- CELF6 modulates triple-negative breast cancer progression by regulating the stability of FBP1 mRNA
- (2020) Xiaowei Yang et al. BREAST CANCER RESEARCH AND TREATMENT
- β-Elemene Enhances radiosensitivity in non-small-cell lung cancer by inhibiting epithelial–mesenchymal transition and cancer-stewm cell traits via Prx-1/NF-kB/iNOS signaling pathway
- (2020) Kun Zou et al. Aging-US
- Cancer statistics, 2019
- (2019) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- miRNA 146a promotes chemotherapy resistance in lung cancer cells by targeting DNA damage inducible transcript 3 (CHOP)
- (2018) Wenfeng Tan et al. CANCER LETTERS
- Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR -mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study
- (2018) Wen-Zhao Zhong et al. LANCET ONCOLOGY
- Metformin reduces liver glucose production by inhibition of fructose-1-6-bisphosphatase
- (2018) Roger W. Hunter et al. NATURE MEDICINE
- β-Elemene Synergizes With Gefitinib to Inhibit Stem-Like Phenotypes and Progression of Lung Cancer via Down-Regulating EZH2
- (2018) Haibo Cheng et al. Frontiers in Pharmacology
- Treatments for EGFR-mutant non-small cell lung cancer (NSCLC): The road to a success, paved with failures
- (2017) Dae Ho Lee PHARMACOLOGY & THERAPEUTICS
- Interplay of DNA methyltransferase 1 and EZH2 through inactivation of Stat3 contributes to β-elemene-inhibited growth of nasopharyngeal carcinoma cells
- (2017) JingJing Wu et al. Scientific Reports
- β-elemene sensitizes hepatocellular carcinoma cells to oxaliplatin by preventing oxaliplatin-induced degradation of copper transporter 1
- (2016) Xiaoqiang Li et al. Scientific Reports
- Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial
- (2015) Jean-Charles Soria et al. LANCET ONCOLOGY
- Loss of FBP1 by Snail-Mediated Repression Provides Metabolic Advantages in Basal-like Breast Cancer
- (2013) Chenfang Dong et al. CANCER CELL
- Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor–Resistant Disease
- (2013) Kadoaki Ohashi et al. JOURNAL OF CLINICAL ONCOLOGY
- Reversion of Multidrug Resistance in a Chemoresistant Human Breast Cancer Cell Line by ß-Elemene
- (2012) Hong-Bin Xu et al. PHARMACOLOGY
- Noncovalent Wild-type–Sparing Inhibitors of EGFR T790M
- (2012) Ho-June Lee et al. Cancer Discovery
- P21 (waf1/cip1) is required for non-small cell lung cancer sensitive to Gefitinib treatment
- (2011) Yi-Fan Zhao et al. BIOMEDICINE & PHARMACOTHERAPY
- Treatment of Non–Small-Cell Lung Cancer with Erlotinib or Gefitinib
- (2011) Vince D. Cataldo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Fructose-1,6-Bisphosphatase Regulates Glucose-Stimulated Insulin Secretion of Mouse Pancreatic β-Cells
- (2010) Ye Zhang et al. ENDOCRINOLOGY
- Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
- (2010) Makoto Maemondo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anti-tumor effect of β-elemene in glioblastoma cells depends on p38 MAPK activation
- (2008) Yi-Qun Yao et al. CANCER LETTERS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started